Die altersbedingte Makuladegeneration beeinträchtigt das zentrale Sehen, das Sie zum Lesen und zur Erkennung von Gesichtern benötigen. Das periphere Sehen, das Sie für die Bewegung in der Umgebung nutzen, bleibt in der Regel erhalten, sodass nicht Ihr gesamtes Sehvermögen verloren geht. Der Verlust des zentralen Sehens ist bereits an sich invalidisierend. Es gibt zwei Formen: Die trockene Form ist häufig und verläuft langsam.
Die feuchte Form ist seltener, verläuft schneller und erfordert eine dringende Behandlung. Die stärkste Maßnahme, die in Ihrer Hand liegt, ist das Nichtrauchen, da es Ihr Risiko für eine fortgeschrittene Erkrankung mehr senkt als jede andere von Ihnen umsetzbare Maßnahme. Bei Personen, die bereits eine intermediäre Erkrankung haben, verlangsamt die AREDS2-Formulierung den Fortschritt zur fortgeschrittenen Erkrankung, verhindert jedoch keine frühe Erkrankung.
Practice Ranking
Every practice we track for Macular Degeneration: What Protects Your Sight, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
4 practices · 3 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Quitting Smoking: What It Does to the Body and the Methods That Actually Work The leading modifiable risk factor for AMD. | Strong | Pro | Free to $$ | Hard | Days to Longer | |
| 2 | The Mediterranean Diet: What It Does, Why It Works, and How to Start Closest Mediterranean-diet adherence tracked with far less advanced AMD; the most empowering everyday lever, on observational evidence. | Moderate | Self-Directed | $ to $$ | Moderate | Months to Longer | |
| 3 | Whole Foods and Ultra-Processed Foods: What the Evidence Shows and How to Eat Well Leafy greens and other carotenoid-rich vegetables tracked with less advanced AMD, feeding the same pigments the eye concentrates in the macula. | Moderate | Self-Directed | $ to $$ | Moderate to Hard | Weeks to Months | |
| 4 | Omega-3 and Fish Oil: Clear on Triglycerides, Mixed on the Heart Despite the theory, adding omega-3 to the eye formula did not slow progression to advanced AMD, so do not rely on fish oil here. | Strong | Supplement | $ to $$ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Age-related macular degeneration damages the macula, the small central patch of retina that carries fine detail. It takes reading, faces, and the center of a scene first. There are two forms. The dry form is the common, slow kind: yellow deposits called drusen collect beneath the central retina, and the light-sensing cells thin. Most people at this early stage hold useful vision for years, and many never progress. The advanced dry stage, geographic atrophy, is patches where central cells have died, leaving blind spots that widen slowly. The dry form can turn wet at any stage: abnormal new vessels grow beneath the macula, and central vision can blur over days to weeks.
What Helps
Most of what protects the macula is not a supplement. Not smoking is the one strongest lever. No food or supplement reduces advanced-disease risk as much, and the risk keeps falling in the years after you quit.
Diet comes next. People who keep closest to a Mediterranean-style plate, and who eat the most leafy greens, develop less advanced disease. Spinach and collard greens carry the most weight, because they are the richest food source of lutein and zeaxanthin.
The AREDS2 supplement helps a narrow group: people whose disease is already intermediate, or advanced in one eye. For them it cuts the risk of progressing to advanced disease by about a quarter over six years, a relative reduction. It does nothing for healthy eyes or early changes. The formula comes in a lutein-and-zeaxanthin version.
For the wet form, a specialist injects anti-VEGF drugs into the eye. For geographic atrophy, a newer class of complement-inhibitor injections slows the patch's growth on retinal scans. So far the scans improve but eyesight does not.
A sudden change in central vision can mean the dry form has turned wet. That is the moment to get a same-day retina review.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Vision
The antioxidant and zinc formula cut progression to advanced AMD by about 25% in intermediate disease
For people who already have moderate macular degeneration, a specific daily antioxidant and zinc supplement lowered the chance of it getting worse by about a quarter over six years, but it did nothing for people with healthy eyes or very early changes, and it cannot bring back lost sight.
In participants with intermediate AMD, or advanced AMD in one eye, a daily formula of vitamin C, vitamin E, beta-carotene and zinc (with copper) reduced the odds of progressing to advanced AMD by about 25% (odds ratio 0.72) and the risk of moderate vision loss by about 19% over a median 6.3 years. Participants with no AMD or only early AMD showed no benefit. Measured in: 3,640 people aged 55 to 80 with a range of AMD severity, randomized to antioxidants plus zinc, antioxidants alone, zinc alone, or placebo. The benefit was confined to those who already had intermediate AMD or advanced AMD in one eye; the formula did not slow anything in people with no AMD or early AMD, and it does not restore vision already lost. This original formula contained beta-carotene, later removed for the reasons in the safety claim.
Who this may not transfer to:Both sexes were enrolled across all AMD severity categories.
The study · 1
Age-Related Eye Disease Study Research Group, high-dose vitamins C and E, beta carotene and zinc for AMD and vision loss: AREDS report no. 8 · Arch Ophthalmol 2001;119(10):1417-36
Adding omega-3 to the formula did not slow progression to advanced AMD
Adding fish-oil (omega-3) to the eye supplement made no difference to whether macular degeneration got worse in the large AREDS2 trial.
Adding omega-3 fatty acids (350 mg DHA plus 650 mg EPA daily) to the AREDS formula produced no significant reduction in progression to advanced AMD compared with the formula without them (hazard ratio 0.97, not significant) over a median five years. Measured in: 4,203 people aged 50 to 85 at high risk of advanced AMD, in a factorial randomized trial. This was the isolated supplement measured against a hard clinical endpoint; oily fish eaten as food still fits the dietary pattern linked to lower risk, which is a separate line of evidence. The trial tested one dose and formulation of DHA and EPA.
Who this may not transfer to:Both sexes were enrolled; the null result applied across the trial population.
The study · 1
Age-Related Eye Disease Study 2 (AREDS2) Research Group, lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial · JAMA 2013;309(19):2005-15
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Anti-VEGF-Injektionen erhielten bei etwa 95 % der feuchten AMD das Sehvermögen, gegenüber 62 % in der Scheingruppe
Bei der feuchten Form der Makuladegeneration erhielten regelmäßige Injektionen, die ein Wachstumssignal namens VEGF blockieren, bei etwa 95 % der Personen das Sehvermögen und ermöglichten etwa einem Drittel die teilweise Wiederherstellung des Sehvermögens, sofern die Behandlung umgehend beginnt.
In MARINA hielt monatliches Ranibizumab nach einem Jahr bei etwa 95 % der Personen mit neovaskulärer AMD das Sehvermögen (weniger als 15 Buchstaben verloren), gegenüber 62 % in der Scheingruppe, und etwa 34 % gewannen 15 oder mehr Buchstaben gegenüber 5 % in der Scheingruppe. In ANCHOR erhielt Ranibizumab das Sehvermögen bei etwa 94 bis 96 % gegenüber 64 % unter photodynamischer Therapie, wobei das mittlere Sehvermögen unter Behandlung zunahm. Measured in: 716 people in MARINA (minimally classic or occult lesions) and 423 in ANCHOR (predominantly classic lesions), both randomized trials. Der Nutzen hängt von einer prompten und fortlaufenden Behandlung ab, und das Studienregime war eine monatliche Injektion; die Injektionen tragen ein geringes Risiko einer intraokulären Infektion und werden von einem Spezialisten verabreicht. Sie behandeln die feuchte Form, nicht die trockene.
Who this may not transfer to:Both trials enrolled men and women aged 50 and older with neovascular AMD.
The studies · 2
Rosenfeld PJ et al., ranibizumab for neovascular age-related macular degeneration (MARINA) · N Engl J Med 2006;355(14):1419-31
Brown DM et al., ranibizumab versus verteporfin for neovascular age-related macular degeneration (ANCHOR) · N Engl J Med 2006;355(14):1432-44
Bevacizumab erzielte bei feuchter AMD dasselbe Sehvermögen wie Ranibizumab zu einem Bruchteil der Kosten
Das deutlich günstigere Medikament Bevacizumab wirkte bei der Erhaltung des Sehvermögens bei feuchter Makuladegeneration etwa so gut wie das teurere Ranibizumab.
Nach einem Jahr war das deutlich günstigere Bevacizumab Ranibizumab bei der Sehschärfe bei neovaskulärer AMD nicht unterlegen, mit mittleren Gewinnen von 8.0 gegenüber 8.5 Buchstaben (Unterschied innerhalb der vorab festgelegten Äquivalenzmarge). Sterblichkeits-, Herzinfarkt- und Schlaganfallraten waren zwischen den Medikamenten ähnlich, obwohl schwerwiegende systemische unerwünschte Ereignisse insgesamt (meist Krankenhauseinweisungen) bei Bevacizumab etwas häufiger waren (24.1 % gegenüber 19.0 %; Risikoverhältnis 1.29, 95 %-KI 1.01 bis 1.66), ein Unterschied, den spätere Analysen nicht konsistent bestätigten. Measured in: 1,208 people with neovascular AMD randomized to bevacizumab or ranibizumab, monthly or as-needed (CATT). Die beiden Medikamente waren beim Sehvermögen gleichwertig, was wichtig ist, weil Bevacizumab nur einen Bruchteil von Ranibizumab kostet; die Studie vermerkte einen kleinen Unterschied bei einigen nicht-okulären schwerwiegenden Ereignissen, den spätere Analysen nicht konsistent bestätigten.
Who this may not transfer to:Both sexes were enrolled; results applied across the trial population.
The study · 1
Martin et al. 2011 (CATT, ranibizumab vs bevacizumab for neovascular AMD) · N Engl J Med 2011;364(20):1897-908
Lutein and zeaxanthin cut progression about 18% more than beta-carotene in the formula
Swapping beta-carotene for two natural eye pigments, lutein and zeaxanthin, worked at least as well at slowing macular degeneration and helped most in people who ate little of them, which is why the newer formula uses them.
In the direct comparison, replacing beta-carotene with lutein (10 mg) plus zeaxanthin (2 mg) was associated with an about 18% further reduction in progression to advanced AMD (hazard ratio 0.82, 95% CI 0.69 to 0.96), and the benefit was largest in participants whose dietary intake of these pigments was lowest. Measured in: Subgroup and secondary analyzes within the 4,203-participant AREDS2 trial. The overall primary comparison of adding lutein and zeaxanthin to the formula was not statistically significant; the 18% figure comes from the pre-specified secondary analysis directly substituting the pigments for beta-carotene, so it is supporting, not confirmatory evidence.
Who this may not transfer to:Both sexes were enrolled in AREDS2; the substitution analysis drew on the full trial.
The studies · 2
Chew et al. 2014 (AREDS2 report no. 3, secondary analyzes of lutein/zeaxanthin) · JAMA Ophthalmol 2014;132(2):142-9
Age-Related Eye Disease Study 2 (AREDS2) Research Group, lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial · JAMA 2013;309(19):2005-15
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Aktuelle Raucher tragen ein etwa zwei- bis dreifaches Risiko für fortgeschrittene AMD
Rauchen ist der größte beeinflussbare Faktor, der das Risiko einer schweren Makuladegeneration um etwa das Zwei- bis Dreifache erhöht, und das Aufhören senkt das Risiko im Laufe der Zeit wieder.
In der Zusammenschau der Beobachtungsstudien war aktuelles Rauchen der konsistenteste veränderliche Risikofaktor für späte AMD, wobei aktuelle Raucher ein etwa zwei- bis dreifach höheres Risiko als Nichtraucher trugen, mit einer klaren Dosis-Wirkungs-Beziehung zu Packungsjahren, und das Risiko sank über Jahre nach dem Aufhören auf das Niveau von Nichtrauchern. Measured in: Systematic reviews and meta-analyzes of population cohort and case-control studies of AMD risk factors. Die zugrunde liegenden Studien sind beobachtend, sodass eine Restverwirrung nicht ausgeschlossen werden kann, aber Größe, Konsistenz und Dosis-Wirkungs-Beziehung der Raucherassoziation machen sie zum stärksten identifizierten veränderbaren Risikofaktor. Die Übersichtsarbeiten berichten über späte AMD insgesamt, ohne klar zwischen trockener und feuchter Form zu trennen.
Who this may not transfer to:The pooled cohorts and case-control studies included both sexes.
The studies · 2
Chakravarthy U et al., clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis · BMC Ophthalmol 2010;10:31
Thornton J et al., smoking and age-related macular degeneration: a review of association · Eye (Lond) 2005;19(9):935-44
Die höchste Adhärenz an die Mittelmeerdiät korrelierte mit etwa 40 % weniger fortgeschrittener AMD
Personen, die sich am nächsten an einer Mittelmeerdiät orientierten, also mehr Gemüse, Obst, Fisch, Nüsse und Olivenöl aßen, hatten ein etwa 40 % geringeres Risiko, die fortgeschrittene Form der Makuladegeneration zu entwickeln.
In der Zusammenschau zweier langer Bevölkerungskohorten hatten Personen im höchsten Quintil der Adhärenz an eine Mittelmeerdiät ein etwa 40 % geringeres Risiko, neu aufgetretene fortgeschrittene AMD zu entwickeln, als diejenigen im niedrigsten (Hazard Ratio etwa 0.59), wobei die Assoziation nach Adjustierung für bekannte Risikofaktoren bestehen blieb. Measured in: 4,996 people in the Rotterdam Study (RS-I) and the Alienor Study, followed for incident advanced AMD (EYE-RISK Consortium). What could explain it instead: Healthy-user bias: people who eat closest to a Mediterranean pattern also tend to be less likely to smoke, more active and of higher socioeconomic status, all of which independently affect AMD risk. The analysis adjusted for measured factors but cannot remove unmeasured ones.. Die Assoziation betraf speziell die fortgeschrittene AMD, und der Effekt für frühe AMD war schwächer. Es handelt sich um Ernährungsmuster-Evidenz, keine Studie, sodass sie einen konsistenten Zusammenhang zeigt, aber keinen Beweis, dass eine Diätänderung das Ergebnis verändert.
Who this may not transfer to:Both cohorts enrolled men and women aged 55 and older.
The study · 1
Merle BMJ et al., Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK Consortium · Ophthalmology 2019;126(3):381-90
Die carotinoidreichsten Gemüsesorten korrelierten mit etwa 43 % weniger fortgeschrittener AMD
Personen, die die meisten carotinoidreichen Gemüsesorten aßen, insbesondere Blattgemüse wie Spinat, hatten ein etwa 40 bis 50 % geringeres Risiko für fortgeschrittene Makuladegeneration.
Personen im höchsten Fünftel der Carotinoidaufnahme hatten ein etwa 43 % geringeres Risiko für fortgeschrittene AMD als diejenigen im niedrigsten (Odds Ratio 0.57). Spinat und Grünkohl, reich an Lutein und Zeaxanthin, zeigten die stärkste individuelle Assoziation, wobei die höchste Aufnahme mit etwa halbem Risiko verbunden war. Measured in: 356 people with advanced AMD and 520 controls in the multicenter Eye Disease Case-Control Study. What could explain it instead: Recall bias and healthy-diet clustering: people eating more leafy greens differ in other health behaviors, and diet was reported after diagnosis, which can color recall.. Als Fallkontrollstudie, bei der Personen nach ihren Essgewohnheiten befragt wurden, ist sie anfällig für Erinnerungsverzerrung und kann keine Kausalität belegen, ist aber der klassische Befund, der erstmals auf die Makulapigmente hindeutete, und stimmt mit der späteren Ernährungsmuster-Evidenz überein.
Who this may not transfer to:Both sexes were included among cases and controls.
The study · 1
Seddon JM et al., dietary carotenoids, vitamins A, C, and E, and advanced AMD (Eye Disease Case-Control Study Group) · JAMA 1994;272(18):1413-20
Pegcetacoplan verlangsamte die geografische Atrophie auf Scans um etwa ein Fünftel, ohne Nutzen für die Sehkraft nach zwei Jahren
Ein neueres injizierbares Medikament, Pegcetacoplan, verlangsamte das Wachstum des toten Flecks bei fortgeschrittener trockener Makuladegeneration auf Scans um etwa ein Fünftel, verbesserte oder schützte die Sehkraft in den Studien jedoch nicht und erhöhte leicht die Wahrscheinlichkeit der feuchten Form.
OAKS und DERBY waren zwei multizentrische, doppelt maskierte, scheinkontrollierte Phase-3-Studien mit 1,258 Menschen ab 60 Jahren mit geografischer Atrophie durch AMD, die randomisiert monatliches oder zweimonatliches intravitreales Pegcetacoplan oder eine Schein-Injektion erhielten. Nach 24 Monaten verlangsamte monatliches Pegcetacoplan das Wachstum der Atrophie-Läsion auf der Fundusautofluoreszenz um 22 % in OAKS (Kleinste-Quadrate-Mittelwertdifferenz -0.90 mm2, 95 %-KI -1.30 bis -0.50) und 19 % in DERBY (-0.75 mm2, -1.15 bis -0.34), wobei der zweimonatliche Arm knapp dahinter lag. Die wichtigsten sekundären Sehfunktions-Endpunkte, einschließlich bestkorrigierter Sehschärfe und funktionellem Lesen, zeigten nach 24 Monaten keinen Unterschied zur Schein-Injektion. Neu auftretende exsudative (feuchte) AMD trat bei 11 % bis 13 % der monatlich injizierten Augen gegenüber 2 % bis 4 % unter Schein-Injektion auf. Das Medikament verlangsamt also verlässlich das strukturelle Fortschreiten, für das es zugelassen wurde, während seine Wirkung auf die tatsächlich genutzte Sehkraft noch nicht nachgewiesen ist.
Who this may not transfer to:Both trials enrolled men and women aged 60 and older with geographic atrophy from AMD; the effect was on the anatomical lesion, not on measured vision.
The study · 1
Heier JS et al., pegcetacoplan for geographic atrophy secondary to AMD (OAKS and DERBY): two phase 3 trials · Lancet 2023;402(10411):1434-48
How It Works
The macula is packed with two yellow pigments, lutein and zeaxanthin, pulled from food and concentrated there. They absorb short-wavelength light and mop up the reactive oxygen that constant light exposure produces. The antioxidants and zinc in the AREDS2 supplement target that same oxidative and metabolic stress on the retinal cells.
In the wet form, stressed retina releases vascular endothelial growth factor, or VEGF, which drives fragile new vessels to grow. Beneath the macula those vessels leak, and central vision blurs. Anti-VEGF drugs bind that signal, so the abnormal vessels shrink back and the leaking settles. Started early, these injections preserve vision for most people who receive them.
What the Research Argues Against
In the AREDS2 trial, adding omega-3 fish oil, the DHA and EPA, to the supplement formula did not slow progression to advanced disease. The isolated fatty acids made no difference to progression, even though a diet with oily fish is tied to lower risk.
Go Deeper
- Mediterranean diet: the eating pattern tied to less advanced disease.
- Omega-3 and fish oil: the capsule that failed the AREDS2 trial, and the food it comes from.
- Inflammation: the process running beneath age-related eye disease.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine has no term for macular degeneration. It reads the failing of central, detailed vision through the eye's classical relationships. The Liver is said to open into the eyes, and its Blood to moisten and brighten them. The Kidney stores the essence that sustains the eyes over a lifetime. So age-related dimming of sight is most often read as a depletion at that Liver and Kidney root. The wet form leaks new vessels under the retina and needs prompt anti-VEGF treatment. The pattern below is not a substitute for that care. The herbs are chosen to fit the pattern. An eye formula that suits a dry, deficient picture can be wrong for a damp or stagnant one.
The most common age-related picture: gradually blurring or dimming central vision, dry eyes, dizziness, tinnitus, low back and knee weakness, and vision that tires by evening. The classical direction is to nourish Liver and Kidney Yin and brighten the eyes, the pattern behind much traditional use of goji and chrysanthemum.
A heavier, foggier presentation: central blur with a sense of fullness, floaters, fatigue after eating, poor appetite, loose stools, and a pale swollen tongue with a greasy coat. The direction is to strengthen the Spleen and transform Damp so the clear Yang can rise to the eyes and the fluids stop pooling below.
This pattern is read when vision has dropped suddenly, or when there is bleeding under the retina: fixed dark spots, a dusky complexion, and a purplish tongue. The direction is to move Blood and free the collaterals. This presentation in particular needs urgent ophthalmic assessment first.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Beta-carotene raised lung cancer in smokers, 2.1% against 0.9% in the eye trial
In AREDS2, lung cancer occurred in 2.1% of participants taking beta-carotene versus 0.9% not taking it, and 91% of those cancers were in former smokers. This matched the earlier CARET trial, where beta-carotene plus vitamin A raised lung cancer incidence by 28% (relative risk 1.28) and total mortality by 17% in current smokers and asbestos-exposed workers, which stopped that trial early. Das erhöhte Lungenkrebsrisiko konzentrierte sich auf aktuelle und ehemalige Raucher, nicht auf Nichtraucher, aber es ist der Grund, warum Beta-Carotin aus der Augenformel entfernt wurde, und warum die Variante mit Lutein und Zeaxanthin die richtige Wahl für alle mit Rauchergeschichte ist.Chew et al. 2014 (AREDS2 report no. 3, secondary analyzes of lutein/zeaxanthin)Omenn GS et al., effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease (CARET)
AREDS2 slows progression; it does not restore lost sight
AREDS2 cannot bring back vision the disease has already taken, and taking it earlier or in higher doses does not change that. High-dose zinc is paired with a little copper, because zinc alone taken long term can lower copper levels.
Beta-carotene, smoking history, and the reformulated formula
Beta-carotene, the pigment in the original formula, raised lung-cancer risk in current and former smokers. The reformulated AREDS2 version substitutes lutein and zeaxanthin. These carry no such signal and matched beta-carotene for effect.
Sourcing eye and wellness herbs safely
Products sold direct to the public for eye health, weight, and general wellness have a documented history of undeclared or substituted ingredients. Species substitution is a known hazard in the herb trade. Buy from regulated suppliers and qualified practitioners who test their material, and let the pattern and a trained herbalist decide the formula.
These treatments each fit one stage of the disease, and none of them helps at every stage.
When to See Someone
Most of protecting your sight is steady and in your own hands. A few situations need a same-day or urgent eye review.
- Straight lines suddenly looking wavy or bent, a new blur or dark spot in the center of your vision, or a quick drop in vision in one eye. This can mean new wet macular degeneration and needs an urgent retina review(seek urgent care)
- A new change on a printed Amsler grid, checked one eye at a time: lines that were straight now wave, or a square goes missing. Act on any new distortion the same day(seek urgent care)
- Sudden painless loss of vision, a curtain or shadow moving across your sight, or a burst of new flashes and floaters. This can mean a retinal detachment or a blocked retinal vessel (an emergency(seek urgent care)
- A plan to start a high-dose eye supplement when you have any smoking history, worth raising before you start
- A new diagnosis of intermediate macular degeneration) the stage at which the AREDS2 formula is worth discussing with your eye specialist
- Growing difficulty with reading, faces, driving, or steps. This is the point to ask about a low-vision assessment and the rehabilitation that goes with it
Macular degeneration moves slowly for most people. The levers with the most effect are yours: not smoking, eating for your eyes, and getting seen fast if the center of your vision changes.
Common Questions
What is the difference between dry and wet macular degeneration?
The dry form is common and slow. The wet form is less common but moves faster, and it causes most of the severe sight loss from this condition. Fragile new vessels grow under the retina and leak fluid or blood. It is the one form with an urgent treatment, the anti-VEGF injection.
Should I take the AREDS2 supplement?
That is a decision for you and your retina specialist. AREDS2 is aimed at eyes already at the intermediate stage, not at healthy eyes or the earliest changes. It cannot bring back vision the disease has already taken.
Is the cheaper wet-AMD injection as good as the expensive one?
By the best test available, yes. Bevacizumab was compared head-to-head against the far pricier ranibizumab for wet AMD, and the two came out equal for vision at one year, at a fraction of the price.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 14 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.